Monoclonal Antibodies Market Size, In-depth Analysis, Growth and Forecast To 2032

Global Monoclonal Antibodies Market- By Source, By Indication, By End User, By Application, By Production Type- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032

Published: Nov 2022 Base Year: 2021 Report ID: BIOT2237
Available Format: Historical Data: 2019 - 2020 Number of Pages: 1 - 245
Category : Biotechnology
Global Monoclonal Antibodies Market Overview:

According to SPER Market Research, the Global Monoclonal Antibodies Market is estimated to reach USD 604.06 billion by 2032 with a CAGR of 11.33%. 

Monoclonal antibody (mAb) treatment is a type of immunotherapy that makes use of monoclonal antibodies to bind precisely to particular proteins or cells. The identical immune cells that make up monoclonal antibodies serve as copies of a distinct parental cell. These antibodies have monovalent affinity, which enables them to attach to a specific antigen when delivered. Due to their site-specificity, monoclonal antibodies are valuable tools for drug detection and purification and have significant applications in molecular biology, biochemistry, and medicine.



The market is primarily driven by an increase in the prevalence of cancer, an increase in the demand for biosimilar monoclonal antibodies that are less expensive, high demand for biologics, an increase in genomics R&D activities, and the introduction of technologically cutting-edge genetic platforms like next-generation sequencing. Additionally, a rise in research partnerships for the creation of a strong drug pipeline, increased patient and physician awareness of the uses of monoclonal antibody (mAb) therapy, and an increase in the approval of blockbuster mAbs for a number of applications all contribute to the market's expansion. The utilization of cutting-edge genetic engineering technology in the production of mAbs, the presence of well-developed healthcare infrastructure, government support for infection control & management, and an increase in the incidence of diseases linked to a sedentary lifestyle are additional factors driving market expansion. However, it is anticipated that low demand in developing nations may limit the market's expansion for monoclonal antibodies. On the other hand, throughout the projection period, growth possibilities in developing markets are anticipated to provide profitable potential.



The monoclonal antibody and pharmaceutical drug markets in the USA are governed by the Food and Drug Administration (FDA), a federal department of the US Department of Health and Human Services. The USFDA's regulatory support for the treatment of uncommon illnesses and rising product releases are anticipated to fuel the expansion of the monoclonal antibody therapeutics market.

Impact of COVID-19 on the Global Monoclonal Antibodies Market  
The COVID-19 outbreak was deemed an international public health emergency by the World Health Organization (WHO) on January 30, 2020. A total of 210 nations throughout the world have been impacted by COVID-19. An unprecedented worldwide public health threat, COVID-19 is expected to have a favourable effect on the market for monoclonal antibodies and the development of monoclonal antibody treatment. The fast creation of several SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) neutralising monoclonal antibodies was driven by the realisation of the urgent need for medicines to be accessible on a worldwide scale (mAbs). Therefore, throughout the projection period, COVID-19 infection increased growth and possibilities for major players of monoclonal antibodies.

Scope of the Report:
 Report Metric Details
 Market size available for years 2019-2032
 Base year considered 2021
 Forecast period 2022-2032
 Segments coveredBy Source, By Indication, By End User, By Application, By Production Type
 Geographies coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa
 Companies CoveredAbbott Laboratories, AbbVie, AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Amgen, Astellas Pharma, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Celgene, Celldex Therapeutics, Daiichi Sankyo Company ltd., Eli Lilly, GenScript, GlaxoSmithKline Plc, Hoffman Roche Ltd, Johnson & Johnson, Merck & Co. Inc., Mylan N.V, Norvatis AG, Novo Nordisk A/S, Pfizer Inc, Sanofi, Seattle genetics, Shanghi Junsi bioscience ltd, Sigma-Aldrich Co. LLC, Teva pharmaceutical industries, Thermofischer Scientific.
Global Monoclonal Antibodies Market Segmentation:

By Source: Based on the Source, Global Monoclonal Antibodies Market is segmented as; Murine, Chimeric, Humanized and Human.

By Indication: Based on the Indication, Global Monoclonal Antibodies Market is segmented as; Cancer (Breast cancer, Colorectal cancer, Lung cancer, Ovarian cancer, Others), Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Others.

By End User: Based on the End User, Global Monoclonal Antibodies Market is segmented as; Hospitals, Research Institutes, Others.

By Application: Based on the Application, Global Monoclonal Antibodies Market is segmented as; Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular and Cerebrovascular, Others.

By Production Type: 
Based on the Production Type, Global Monoclonal Antibodies Market is segmented as; In Vivo and In Vitro.

By Region: The availability of a highly established healthcare infrastructure, strong patient awareness, and expanding opportunities for cancer research, among other reasons, contributed to North America having the greatest market share.

1. Introduction
1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges 
4.2. COVID-19 Impacts of the Global Monoclonal Antibodies Market 

5. Market variables and outlook
5.1. SWOT analysis 
5.1.1 Strengths 
5.1.2 Weaknesses 
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis 
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape 
5.2.4 Technological landscape 
5.2.5 Environmental landscape 
5.2.6 Legal landscape 
5.3. PORTER’S five forces analysis 
5.3.1 Bargaining power of suppliers 
5.3.2 Bargaining power of Buyers 
5.3.3 Threat of Substitute 
5.3.4 Threat of new entrant 
5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global Monoclonal Antibodies Market, By Source, 2019-2032 (USD Million)
6.1 Murine
6.2 Chimeric
6.3 Humanized
6.4 Human

7. Global Monoclonal Antibodies Market, By Indication, 2019-2032 (USD Million)
7.1 Cancer
7.1.1 Breast cancer
7.1.2 Colorectal cancer 
7.1.3 Lung cancer
7.1.4 Ovarian cancer
7.1.5 Others
7.2 Autoimmune Diseases
7.3 Inflammatory Diseases
7.4 Infectious Diseases
7.5 Others

8. Global Monoclonal Antibodies Market, By End User, 2019-2032 (USD Million)
8.1 Hospitals
8.2 Research Institutes
8.3 Others

9. Global Monoclonal Antibodies Market, By Application, 2019-2032 (USD Million)
9.1 Anti-Cancer 
9.2 Immunological 
9.3 Anti-Infective Monoclonal Antibodies (MAbs) 
9.4 Neuropharmacological 
9.5 Cardiovascular And Cerebrovascular 
9.6 Others

10. Global Monoclonal Antibodies Market, By Production Type, 2019-2032 (USD Million)
10.1 In Vivo
10.2 In Vitro

11. Global Monoclonal Antibodies Market, By Region, 2019-2032 (USD Million)
11.1 North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2 Europe
11.2.1. Germany
11.2.2. United Kingdom
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3 Asia-Pacific
11.3.1. China
11.3.2. Japan
11.3.3. India
11.3.4. Australia
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4 South America
11.4.1. Brazil
11.4.2. Argentina
11.4.3. Rest of South America
11.5 Middle East & Africa
11.5.1. Kingdom of Saudi Arabia 
11.5.2. United Arab Emirates
11.5.3. Rest of Middle East & Africa

12. Company Profiles

12.1 Abbott Laboratories
12.1.1. Company details 
12.1.2. Financial outlook
12.1.3. Product summary 
12.1.4. Recent developments

12.2 AbbVie
12.2.1. Company details 
12.2.2. Financial outlook
12.2.3. Product summary 
12.2.4. Recent developments

12.3 AbGenomics
12.3.1. Company details 
12.3.2. Financial outlook
12.3.3. Product summary 
12.3.4. Recent developments

12.4 ADC Therapeutics
12.4.1. Company details 
12.4.2. Financial outlook
12.4.3. Product summary 
12.4.4. Recent developments

12.5 Agensys
12.5.1. Company details 
12.5.2. Financial outlook
12.5.3. Product summary 
12.5.4. Recent developments

12.6 Alexion Pharmaceuticals
12.6.1. Company details 
12.6.2. Financial outlook
12.6.3. Product summary 
12.6.4. Recent developments

12.7 ALMAC Group
12.7.1. Company details 
12.7.2. Financial outlook
12.7.3. Product summary 
12.7.4. Recent developments

12.8 Ambrx
12.8.1. Company details 
12.8.2. Financial outlook
12.8.3. Product summary 
12.8.4. Recent developments

12.9 Amgen
12.9.1. Company details 
12.9.2. Financial outlook
12.9.3. Product summary 
12.9.4. Recent developments

12.10 Astellas Pharma
12.10.1. Company details 
12.10.2. Financial outlook
12.10.3. Product summary 
12.10.4. Recent developments

12.11 AstraZeneca plc
12.11.1. Company details 
12.11.2. Financial outlook
12.11.3. Product summary 
12.11.4. Recent developments

12.12 Bayer AG
12.12.1. Company details 
12.12.2. Financial outlook
12.12.3. Product summary 
12.12.4. Recent developments

12.13 Bristol-Myers Squibb
12.13.1. Company details 
12.13.2. Financial outlook
12.13.3. Product summary 
12.13.4. Recent developments

12.14 Celgene
12.14.1. Company details 
12.14.2. Financial outlook
12.14.3. Product summary 
12.14.4. Recent developments

12.15 Celldex Therapeutics
12.15.1. Company details 
12.15.2. Financial outlook
12.15.3. Product summary 
12.15.4. Recent developments

12.16 Daiichi Sankyo Company ltd.
12.16.1. Company details 
12.16.2. Financial outlook
12.16.3. Product summary 
12.16.4. Recent developments

12.17 Eli Lilly
12.17.1. Company details 
12.17.2. Financial outlook
12.17.3. Product summary 
12.17.4. Recent developments

12.18 GenScript
12.18.1. Company details 
12.18.2. Financial outlook
12.18.3. Product summary 
12.18.4. Recent developments

12.19 GlaxoSmithKline Plc
12.19.1. Company details 
12.19.2. Financial outlook
12.19.3. Product summary 
12.19.4. Recent developments

12.20 Hoffman Roche Ltd
12.20.1. Company details 
12.20.2. Financial outlook
12.20.3. Product summary 
12.20.4. Recent developments

12.21 Johnson & Johnson
12.21.1. Company details 
12.21.2. Financial outlook
12.21.3. Product summary 
12.21.4. Recent developments

12.22 Merck & Co. Inc.
12.22.1. Company details 
12.22.2. Financial outlook
12.22.3. Product summary 
12.22.4. Recent developments

12.23 Mylan N.V
12.23.1. Company details 
12.23.2. Financial outlook
12.23.3. Product summary 
12.23.4. Recent developments

12.24 Norvatis AG
12.24.1. Company details 
12.24.2. Financial outlook
12.24.3. Product summary 
12.24.4. Recent developments

12.25 Novo Nordisk A/S
12.25.1. Company details 
12.25.2. Financial outlook
12.25.3. Product summary 
12.25.4. Recent developments

12.26 Pfizer Inc
12.26.1. Company details 
12.26.2. Financial outlook
12.26.3. Product summary 
12.26.4. Recent developments

12.27 Sanofi 
12.27.1. Company details 
12.27.2. Financial outlook
12.27.3. Product summary 
12.27.4. Recent developments

12.28 Seattle genetics
12.28.1. Company details 
12.28.2. Financial outlook
12.28.3. Product summary 
12.28.4. Recent developments

12.29 Shanghi Junsi bioscience ltd
12.29.1. Company details 
12.29.2. Financial outlook
12.29.3. Product summary 
12.29.4. Recent developments

12.30 Sigma-Aldrich Co. LLC
12.30.1. Company details 
12.30.2. Financial outlook
12.30.3. Product summary 
12.30.4. Recent developments

12.31 Teva pharmaceutical industries
12.31.1. Company details 
12.31.2. Financial outlook
12.31.3. Product summary
12.31.4. Recent developments

12.32 Thermofischer Scientific
12.32.1. Company details 
12.32.2. Financial outlook
12.32.3. Product summary 
12.32.4. Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3


Frequently Asked Questions About This Report
The key players in the market include Companies Covered Abbott Laboratories, AbbVie, AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Amgen, Astellas Pharma, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Celgene, Celldex Therapeutics, Daiichi Sankyo Company ltd., Eli Lilly, GenScript, GlaxoSmithKline Plc, Hoffman Roche Ltd, Johnson & Johnson, Merck & Co. Inc., Mylan N.V, Norvatis AG, Novo Nordisk A/S, Pfizer Inc, Sanofi, Seattle genetics, Shanghi Junsi bioscience ltd, Sigma-Aldrich Co. LLC, Teva pharmaceutical industries, Thermofischer Scientific.
Additional factors driving market expansion include the availability of well-developed healthcare infrastructure, government assistance for infection prevention and management, and an increase in the frequency of diseases associated with sedentary lifestyles.
The Monoclonal Antibodies Market is projected to reach USD 604.06 billion by 2030, growing at a CAGR of 11.33% during the forecast period.
The Monoclonal Antibodies Market grew in market size from 2021. The Market is expected to reach USD 604.06 billion by 2030, at a CAGR of 11.33% during the forecast period.
The Monoclonal Antibodies Market CAGR of 11.33% during the forecast period.
The Monoclonal Antibodies Market size is USD 604.06 billion from 2022 to 2030.
The Monoclonal Antibodies Market segment is Covered By Source, By Indication, By End User, By Application, By Production Type.
The North America and Europe region is anticipated to have the highest market share in the Monoclonal Antibodies Market.
Not able to find what you are looking for? Need customization in the existing report?
Click Here
PLACE AN ORDER
  • 15% off
     
    $ 4250
  • 20% off
             
    $ 5650
  • 25% off
         
    $ 7450
Pre-Purchase Inquiry
SEND AN INQUIRY
NEED CUSTOMIZATION?
Request Customization
100% Secure Payment

SPER American Express
SPER VISA
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB

SPER

Market Research

We are the leading, full-service global market research and consulting company.

Certificates
iso-1 iso-1
Secure Payments
SPER Payment Options
Connect with us